371 related articles for article (PubMed ID: 18844975)
21. Implication of the JNK pathway in a rat model of Huntington's disease.
Perrin V; Dufour N; Raoul C; Hassig R; Brouillet E; Aebischer P; Luthi-Carter R; Déglon N
Exp Neurol; 2009 Jan; 215(1):191-200. PubMed ID: 19022249
[TBL] [Abstract][Full Text] [Related]
22. Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis.
Li SH; Lam S; Cheng AL; Li XJ
Hum Mol Genet; 2000 Nov; 9(19):2859-67. PubMed ID: 11092762
[TBL] [Abstract][Full Text] [Related]
23. Arfaptin 2 regulates the aggregation of mutant huntingtin protein.
Peters PJ; Ning K; Palacios F; Boshans RL; Kazantsev A; Thompson LM; Woodman B; Bates GP; D'Souza-Schorey C
Nat Cell Biol; 2002 Mar; 4(3):240-5. PubMed ID: 11854752
[TBL] [Abstract][Full Text] [Related]
24. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
[TBL] [Abstract][Full Text] [Related]
25. Glutathione redox cycle dysregulation in Huntington's disease knock-in striatal cells.
Ribeiro M; Rosenstock TR; Cunha-Oliveira T; Ferreira IL; Oliveira CR; Rego AC
Free Radic Biol Med; 2012 Nov; 53(10):1857-67. PubMed ID: 22982598
[TBL] [Abstract][Full Text] [Related]
26. How does the Huntington's disease mutation damage cells?
Rubinsztein DC
Sci Aging Knowledge Environ; 2003 Sep; 2003(37):PE26. PubMed ID: 13679594
[TBL] [Abstract][Full Text] [Related]
27. Huntington's disease: from pathology and genetics to potential therapies.
Imarisio S; Carmichael J; Korolchuk V; Chen CW; Saiki S; Rose C; Krishna G; Davies JE; Ttofi E; Underwood BR; Rubinsztein DC
Biochem J; 2008 Jun; 412(2):191-209. PubMed ID: 18466116
[TBL] [Abstract][Full Text] [Related]
28. ATF3 plays a protective role against toxicity by N-terminal fragment of mutant huntingtin in stable PC12 cell line.
Liang Y; Jiang H; Ratovitski T; Jie C; Nakamura M; Hirschhorn RR; Wang X; Smith WW; Hai T; Poirier MA; Ross CA
Brain Res; 2009 Aug; 1286():221-9. PubMed ID: 19559011
[TBL] [Abstract][Full Text] [Related]
29. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum.
Grondin R; Kaytor MD; Ai Y; Nelson PT; Thakker DR; Heisel J; Weatherspoon MR; Blum JL; Burright EN; Zhang Z; Kaemmerer WF
Brain; 2012 Apr; 135(Pt 4):1197-209. PubMed ID: 22252996
[TBL] [Abstract][Full Text] [Related]
30. Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction.
Goswami A; Dikshit P; Mishra A; Mulherkar S; Nukina N; Jana NR
Biochem Biophys Res Commun; 2006 Mar; 342(1):184-90. PubMed ID: 16472774
[TBL] [Abstract][Full Text] [Related]
31. Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation.
Igarashi S; Morita H; Bennett KM; Tanaka Y; Engelender S; Peters MF; Cooper JK; Wood JD; Sawa A; Ross CA
Neuroreport; 2003 Mar; 14(4):565-8. PubMed ID: 12657886
[TBL] [Abstract][Full Text] [Related]
32. Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum.
Régulier E; Trottier Y; Perrin V; Aebischer P; Déglon N
Hum Mol Genet; 2003 Nov; 12(21):2827-36. PubMed ID: 12952868
[TBL] [Abstract][Full Text] [Related]
33. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.
Truant R; Atwal RS; Burtnik A
Prog Neurobiol; 2007 Nov; 83(4):211-27. PubMed ID: 17240517
[TBL] [Abstract][Full Text] [Related]
34. Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin.
Olson SD; Kambal A; Pollock K; Mitchell GM; Stewart H; Kalomoiris S; Cary W; Nacey C; Pepper K; Nolta JA
Mol Cell Neurosci; 2012 Mar; 49(3):271-81. PubMed ID: 22198539
[TBL] [Abstract][Full Text] [Related]
35. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
[TBL] [Abstract][Full Text] [Related]
36. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
37. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
Apostol BL; Simmons DA; Zuccato C; Illes K; Pallos J; Casale M; Conforti P; Ramos C; Roarke M; Kathuria S; Cattaneo E; Marsh JL; Thompson LM
Mol Cell Neurosci; 2008 Sep; 39(1):8-20. PubMed ID: 18602275
[TBL] [Abstract][Full Text] [Related]
38. Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death.
Gong B; Lim MC; Wanderer J; Wyttenbach A; Morton AJ
Brain Res Bull; 2008 Jan; 75(1):146-57. PubMed ID: 18158109
[TBL] [Abstract][Full Text] [Related]
39. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.
Valencia A; Reeves PB; Sapp E; Li X; Alexander J; Kegel KB; Chase K; Aronin N; DiFiglia M
J Neurosci Res; 2010 Jan; 88(1):179-90. PubMed ID: 19642201
[TBL] [Abstract][Full Text] [Related]
40. Huntingtin's WW domain partners in Huntington's disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington's disease pathogenesis.
Passani LA; Bedford MT; Faber PW; McGinnis KM; Sharp AH; Gusella JF; Vonsattel JP; MacDonald ME
Hum Mol Genet; 2000 Sep; 9(14):2175-82. PubMed ID: 10958656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
